Drug intelligence / Profile preview

He Xue Tong Mai

Development stage: Unknown
Lead developer: Liaoning University of Traditional Chinese Medicine
Administration: Oral

Overview

He Xue Tong Mai particles is a Traditional Chinese Medicine (TCM) formulation currently under investigation in clinical trials. It is being studied for its therapeutic potential in treating Angina pectoris when combined with arterial atherosclerotic cerebral infarction. The research specifically focuses on its efficacy in addressing the 'Phlegm and blood stenosis syndrome' within the framework of TCM diagnostics.

Other names: He Xue Tong Mai particles和血通脉颗粒

Beyond the preview

Go deeper on He Xue Tong Mai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on He Xue Tong Mai.

Explore the full profile